Navigation Links
Cytokinetics to Announce First Quarter Results on April 30, 2015
Date:4/16/2015

South San Francisco, CA (PRWEB) April 16, 2015

Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 30, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investor Relations section of Cytokinetics’ website at http://www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 34463154.

An archived replay of the webcast will be available via Cytokinetics' website until April 30, 2015. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 34463154 from April 30, 2015 at 5:30 PM Eastern Time until May 7, 2015.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle activator, as a potential treatment for amyotrophic lateral sclerosis (ALS). Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at http://www.cytokinetics.com/.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics’ drug candidates and potential drug candidates, as well as statements relating to Cytokinetics’ and its partners’ research and development activities. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

Contact:
Joanna L. Goldstein    
Manager, Investor Relations & Corporate Communications
(650) 624-3000

Read the full story at http://www.prweb.com/releases/2015/04/prweb12660435.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases
2. Cytokinetics Announces Completion of Enrollment in COSMIC-HF
3. Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis
4. Cytokinetics to Present at the 14th Annual Needham Healthcare Conference
5. Cytokinetics to Host R&D Day on Tuesday, May 12, 2015
6. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
7. Annual Conference about Technology Solutions for People with Disabilities Announces Program
8. Probiotic Action Announces Probiotics Lead the Digestive Health Market
9. Verenium Announces Preliminary Financial Results For Fiscal 2012
10. DMG is Proud to Announce that CD Diagnostics will be Featured in an Upcoming Episode of Health Heroes
11. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2020)... , ... June 03, 2020 , ... ... highlight various applications of biofeedback. In the next installment, Dr. Inna Khazan will ... whereby individuals learn to bring their attention to the feelings, thoughts, and emotions ...
(Date:5/30/2020)... ... May 29, 2020 , ... The Conference Forum is pleased ... dedicated to the unique role of the Chief Medical Officer in the biotech ... problem-solving, best practices and career development of CMOs and Heads of R&D from ...
(Date:5/26/2020)... MENLO PARK, Calif. (PRWEB) , ... May 26, 2020 , ... ... Genie , the most recognized brand of smart garage door openers, announce a new ... full line of Wi-Fi enabled garage door openers powered by Aladdin Connect® can now ...
(Date:5/21/2020)... , ... May 19, 2020 , ... Eaton Square is ... addition of Popper and Company, a biotechnology and medical technology-focused strategy and M&A advisory ... grow in the United States, linking US and Asia Pacific healthcare innovators with capital ...
Breaking Biology Technology:
(Date:6/25/2020)... ... 2020 , ... eClinical Solutions LLC , a leading ... drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on randomized ... COVID-19. This is the first study of an XPO1 inhibitor in patients with ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... is pleased to announce the next event in a series of TOPIQ webinars, ... The TOPIQ series of webinars was developed in response to social distancing measures ...
(Date:6/19/2020)... , ... June 18, 2020 , ... Join experts from ... PhD, Principal Scientist in a live webinar on Wednesday, July 8, 2020 ... simplified the way we genetically engineer new models. However, while modifying the genome may ...
Breaking Biology News(10 mins):